Clinical trials: Thoracic Diseases
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in chemo-naive elderly patients with advanced non-small cell lung cancer.
- Trial name
- NCT01196078
- Testing
- erlotinib [Tarceva], vinorelbine
- Where
- Taiwan
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Non-Small Cell
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT00073008
- Testing
- GW572016 (lapatinib)
- Where
- 31 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Cancer
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects…
- Trial name
- NCT01336634
- Testing
- Dabrafenib, Trametinib
- Where
- 50 sites in United States, France and 9 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease, Myocardial Ischemia
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
The purpose of this study is to evaluate the safety and feasibility of a new coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle.
- Trial name
- MEND II (NCT02189499)
- Testing
- AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
- Where
- 4 sites in Colombia
- Volunteers
- 42 people
- Sponsor
- Amaranth Medical Inc.
Advanced Cancer, Lung Cancer
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with…
- Conditions
- Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- TIG-006 (NCT05060432)
- Testing
- EOS-448, pembrolizumab, inupadenant
- Where
- 42 sites in United States, Belgium and 4 more
- Volunteers
- 153 people
- Sponsor
- iTeos Belgium SA
Advanced Malignant Solid Tumor, Advanced Lung Cancer
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness.
- Conditions
- Advanced Malignant Solid Tumor, Advanced Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT07110363
- Testing
- BT02
- Volunteers
- 58 people
- Sponsor
- Biotroy Therapeutics
Lung Cancer
T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T138067 in treating patients who have locally advanced…
- Trial name
- NCT00022243
- Testing
- batabulin sodium
- Where
- 2 sites in United States
- Sponsor
- Tularik
Non Small Cell Lung Cancer
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT01031225
- Testing
- STA 9090
- Where
- 21 sites in United States
- Volunteers
- 113 people
- Sponsor
- Synta Pharmaceuticals Corp.
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- HS-20117 (NCT06621563)
- Testing
- HS-20117 combined HS-20093, HS-20117 combined Platinum-containing chemotherapy, HS-20117 combined HS-20093 and 5-FU
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Hansoh BioMedical R&D Company
Lung Neoplasms
POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
This is a prospective, multicenter, single-arm study on transbronchial microwave ablation using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris…
- Trial name
- NCT05299606
- Testing
- Transbronchial Microwave Ablation
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 12 people
- Sponsor
- Ethicon, Inc.
Advanced Solid Tumors, Ovarian Cancer
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
- Trial name
- NCT02367352
- Testing
- Alisertib, Paclitaxel
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 9 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Bronchitis
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
A study to assess the safety and efficacy of moxifloxacin compared to that of amoxicillin-clavulanic acid for the treatment of subjects with acute exacerbation of chronic bronchitis.
- Trial name
- NCT00656747
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Amoxicillin clavulanic acid
- Where
- 220 sites in Andorra, Argentina and 29 more
- Volunteers
- 1,372 people
- Sponsor
- Bayer
Neoplasms,, Metastatic Cancer,
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
The objective of this study will be to investigate the safety and tolerability of AZD6244 given monotherapy or in combination with docetaxel as 2nd line therapy in Japanese patients with Advanced Solid Malignancies or Locally…
- Conditions
- Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, Advanced Solid Malignancies
- Trial name
- NCT01605916
- Testing
- AZD6244
- Where
- 3 sites in Japan
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Carcinoma
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
- Trial name
- NCT00080340
- Testing
- TLK286 (Telcyta) HCl for Injection, gefitinib (Iressa)
- Where
- 338 sites in United States, Argentina and 6 more
- Volunteers
- 520 people
- Sponsor
- Telik
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to evaluate whether telisotuzumab adizutecan improves response rate and…
- Trial name
- NCT07821684
- Testing
- Telisotuzumab Adizutecan, Docetaxel, Ramucirumab
- Volunteers
- 660 people
- Sponsor
- AbbVie
Carcinoma, Non-Small-Cell Lung
Predictive Assay for Decision Making in Adjuvant Therapy
Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA (tumor < or = 5cm, node negative) Non-squamous Non-Small Lung Cancer (NSCLC) Identified as High, Intermediate, or…
- Trial name
- PADMA (NCT05032352)
- Testing
- Adjuvant, Observation
- Where
- 18 sites in United States
- Volunteers
- 55 people
- Sponsor
- Insight Molecular Diagnostics
Non Small Cell Lung Cancer
FRAME-001 Personalized Vaccine in NSCLC
Despite encouraging results of programmed cell death protein -1 (PD-1) immune checkpoint inhibitor treatment combined with chemotherapy in advanced non-small cell lung cancer (NSCLC), only the minority of approximately 20% of…
- Trial name
- NCT04998474
- Testing
- FRAME-001 personalized vaccine
- Where
- 3 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Frame Pharmaceuticals B.V.
Non-Small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or…
- Trial name
- NCT07680790
- Testing
- Iza-bren, Osimertinib, Pemetrexed
- Where
- 204 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.